Initiation of Anticoagulation in Atrial Fibrillation
Anticoagulation is recommended for patients with non‑valvular atrial fibrillation (AF) who have a CHA₂DS₂‑VASc score indicating elevated stroke risk. High‑risk men are defined as CHA₂DS₂‑VASc ≥ 2 and high‑risk women as CHA₂DS₂‑VASc ≥ 3; these patients should receive oral anticoagulation promptly after diagnosis【S1】. The 2023 ACC/AHA/ACCP/HRS guideline endorses this risk‑based approach and identifies direct oral anticoagulants (DOACs) as first‑line therapy over warfarin for eligible patients【S2】【S3】.
Risk Stratification
- CHA₂DS₂‑VASc components: Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes, Stroke/TIA/thromboembolism (2 points), Vascular disease, Age 65‑74 years, Sex female.
- Score thresholds:
- 0 (men) or 1 (women) – No anticoagulation recommended.
- 1 (men) or 2 (women) – Consider anticoagulation based on patient preference and bleeding risk.
- ≥ 2 (men) or ≥ 3 (women) – Anticoagulation indicated【S1】.
Choice of Anticoagulant
- DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for most patients without contraindications【S2】【S3】.
- Dose adjustment is required for renal impairment, low body weight, or interacting medications per individual drug labeling.
Timing of Initiation
- Initiate anticoagulation as soon as the CHA₂DS₂‑VASc threshold is met and no absolute contraindication (e.g., active major bleeding, severe thrombocytopenia) exists【S2】.
- For patients presenting with recent ischemic stroke, defer anticoagulation for 3–14 days depending on infarct size and hemorrhagic transformation risk, then resume per guideline recommendations【S2】.
Special Situations
- Left atrial appendage occlusion (LAAO): Short‑term post‑procedure anticoagulation with a DOAC is reasonable, often for 45 days, to allow device endothelialization【S5】.
- Heart failure comorbidity: Presence of heart failure does not alter the CHA₂DS₂‑VASc‑based indication for anticoagulation; anticoagulation reduces stroke risk irrespective of ejection fraction【S4】.
Bleeding Risk Assessment
- Assess bleeding risk using tools such as the HAS‑BLED score, but do not withhold anticoagulation solely for a high bleeding score; instead, address modifiable risk factors and consider dose reduction or alternative strategies if necessary【S2】.